Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36605 | 0.90 | CA12 (0.38) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL1616252 | 0.83 | CA12 (0.38) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL5051918 | 0.82 | CA12 (0.42) | TDP1CA12CA1CA9PREP | |
| SCHEMBL26763405 | 0.82 | CA12 (0.42) | TDP1CA12CA1CA9PREP | |
| SCHEMBL413810 | 0.77 | HSP90AA1 (0.47) | TP53TDP1CA12CA1CA9 | |
| SCHEMBL25510387 | 0.76 | PTGS2 (0.51) | TP53TDP1CA12CA1CA9 | |
| SCHEMBL4406786 | 0.75 | CA12 (0.38) | CA12CA1CA9PREP | |
| SCHEMBL37002 | 0.75 | PREP (0.43) | TDP1CA12CA1CA9PREP | |
| SCHEMBL7193989 | 0.74 | CYP1A1 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL4455795 | 0.74 | TDP1 (0.45) | TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654096-B2 | Xyloside derivatives of resveratrol for use thereof in cosmetics | L'OREAL (FR) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654096-B2 | Xyloside derivatives of resveratrol for use thereof in cosmetics | SIRT1, SIRT3, DCXR | TP53 678/4885TDP1 487/4885CA12 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.